To investigate the specific targeted ability and accumulated efficiency of mPEG × HER2-modified nanoparticle drug to HER2-overexpressed ovarian tumor in vivo, we established a human ovarian carcinoma-xenografted model by subcutaneously inoculating HER2+ SKOV-3 cells at the hind foot of nude mice and intravenously treating with mPEG × HER2− or mPEG × DNS-modified far red-labeled liposomes (PEGylated liposomal DiR; Lipo-DiR), respectively, when tumor size had grown to 200 mm3. This evidence concerns the gene ERBB2 and ovarian carcinoma.